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Polycystic ovary syndrome (PCOS) is a common endocrine disorder, with complex etiology and pathophysiology, which remains
poorly understood. It affects about 5–10% of women of reproductive age who typically suffer from obesity, hyperandrogenism,
ovarian dysfunction, andmenstrual irregularity. Indeed, PCOS is themost common cause of anovulatory infertility in industrialized
nations, and it is associated with insulin resistance, type 2 diabetes mellitus, and increased cardiovascular risk. Although insulin
resistance is not included as a criterion for diagnosis, it is a critical pathological condition of PCOS.The purpose of this systematic
review is the analysis of recent randomized clinical trials of inositol(s) in PCOS, in particular myo- and D-chiro-inositol, in order
to better elucidate their physiological involvement in PCOS and potential therapeutic use, alone and in conjunction with assisted
reproductive technologies, in the clinical treatment of women with PCOS.
1. Introduction
Polycystic ovary syndrome (PCOS) is one of the most com-
mon endocrine disorders affecting women of reproductive
age. PCOS is associatedwith awide range ofmaladies, such as
hormonal and metabolic impairments, ovarian dysfunction,
and menstrual irregularity. According to the Rotterdam
criteria developed in 2003, PCOS is diagnosed if two out
of the three following features are met: chronic oligo- or
anovulation, anatomically polycystic ovaries on ultrasonog-
raphy, and clinical and/or biochemical hyperandrogenism
[1]. Although not included as criteria, insulin resistance and
hyperinsulinemia are important etiologic factors associated
with the typical clinical signs and hormonal disorders of
PCOS. Indeed, insulin resistance along with hyperinsuline-
mia affects approximately 40–50% of PCOS patients, both
lean and obese [2–6]; however, in obese women with PCOS
the prevalence of insulin resistance accompanied by com-
pensatory hyperinsulinemia approaches 80% [7]. Treatment
of PCOS with insulin-sensitizing drugs, such as metformin,
troglitazone, and pioglitazone, has been shown to improve
ovulatory function and reduce circulating androgens, corrob-
orating the critical link between insulin resistance and the
pathogenesis of this syndrome. Of these insulin-sensitizing
agents, metformin is most commonly used in the treatment
of PCOS, although it has no official indication outside of type
2 diabetes in many countries and therefore it is considered as
an off-label product when used in nondiabetic women with
PCOS. Nevertheless, nausea, diarrhea, and weight increase
are side effects of metformin, which reduce patients’ compli-
ance and the suitability of its use [3, 8, 9].
In the past two decades, several studies have reported
the effectiveness of inositol(s), mainly the two stereoisomers
myo-inositol (Myo-Ins) and D-chiro-inositol (D-chiro-Ins),
in improving the pathological conditions associated with
PCOS [3, 8–14]. Indeed, Myo-Ins and D-chiro-Ins have
been shown to play different roles in the physiology and
treatment of PCOS [15]. In the ovary, D-chiro-Ins is involved
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in insulin-mediated androgen synthesis [16], whereas Myo-
Insmediates glucose uptake and follicle stimulating hormone
(FSH) signaling [14, 15, 17, 18]. In human ovaries, 99% of
the intracellular pool of inositol consists of Myo-Ins and
the remaining part consists of D-chiro-Ins [17]; imbalance
of ovarian Myo-Ins and D-chiro-Ins concentrations, like a
putative Myo-Ins deficiency, might impair the FSH signal-
ing, as observed in PCOS patients [17–19]. D-chiro-Ins is
synthetized from Myo-Ins through the epimerase enzyme,
which in turn is stimulated by insulin [19]. The epimerase
activity is increased in the theca cells, causing a deficit of
Myo-Ins [19] and this appears to be a critical factor in the
pathogenesis of PCOS. Indeed, reduced intraovarianMyo-Ins
may adversely affect glucose uptake and metabolism of both
oocytes and follicular cells. Since oocytes are characterized
by high glucose consumption this would compromise oocyte
quality.
Several studies have emphasized the pivotal role of Myo-
Ins in improving oocyte quality [10, 14, 25, 31, 32]. Myo-Ins
and D-chiro-Ins are intracellularly incorporated into inositol
phosphoglycans (IPGs), which are second messengers of
insulin, and some actions of insulin are mediated by these
IPG mediators. A number of studies have suggested that
insulin pathway impairment could be due to dysregulation
of the IPG second messenger system [33, 34]. This is con-
sonant with the studies of Nestler et al. which suggest that
altered metabolism of inositol or IPG mediators contribute
to the insulin resistance of women with PCOS [13]. Indeed,
they have demonstrated that D-chiro-Ins supplementation
replenished stores of the mediator and improved insulin
sensitivity in both lean and obese women with PCOS
[12, 13].
Given the physiologic role of inositol(s) in oocyte and
spermatozoa development, the 2013 Florence International
Consensus Conference on myo- and D-chiro-inositol in
obstetrics and gynecology addressed the use of inositol(s) in
assisted reproductive technologies (ART) [35]. In addition,
a previous systematic review by Unfer et al. provided an
overviewof the clinical outcomes ofMyo-Ins as a treatment to
improve ovarian function, as well as hormonal andmetabolic
parameters, in PCOS women [14]. In the present systematic
review, we present updated information about inositol(s),
in particular Myo-Ins and D-chiro-Ins, through an analysis
of recently published reports, in order to better outline the
physiological involvement and clinical use of inositol(s) in
PCOS and ART.
2. Methods
A critical review of the literature was performed by searching
core databases to select pertinent scientific articles: Medline,
Amed, and theCochrane Library.We conducted a search over
the period from January 1999 toMay 2016, and only random-
ized controlled trials (RCTs), involving women with PCOS,
were included in the present study. Search terms included
“inositol,” “myo-inositol,” “D-chiro-inositol,” “polycystic
ovary syndrome,” “oocyte quality,” “ovarian stimulation,” “in
vitro fertilization,” “ovarian function,” and “insulin resis-
tance.” No language restrictions were imposed. Data from
treatments withMyo-Ins or D-chiro-Ins in combination with
other drugs, as well as animal and in vitro investigations,
were excluded. Full articles were obtained through either
our own library or interlibrary loan, for all published studies
that were considered eligible for inclusion in the review. As
described below, a total of 12 studies were finally included for
review.
Themain outcomeswe aimed to focus onwere the follow-
ing: glucose and insulin sensitivity, 17𝛽-estradiol (E2), testos-
terone (T), androstenedione (A), the homeostatic model
assessment (HOMA) index, sex hormone binding globulin
(SHGB), r-FSH, stimulation days, oocyte quality, embryo
quality, biochemical pregnancies, and pregnancy rate.
3. Results of the Literature Search
The systematic search yielded 102 papers for consideration. A
total of 69 studies were excluded during the screening phase
as not being pertinent. Of the remaining 33 studies, 21 did
not meet the selection criteria. This left 12 studies that were
included and analyzed in the final review (Tables 1, 2, 3, and
4). All the RCTs analyzed in this review studied patients with
PCOS.
Eight trials evaluated the effect ofMyo-Ins administration
on hormonal levels and oocyte quality [10, 11, 20, 21, 25–
27, 29]. In one trial, the effects of different concentrations of
D-chiro-Ins on the oocytes quality were assessed [28]. Three
RCTs evaluated the effects of combined therapywithMyo-Ins
and D-chiro-Ins on oocyte quality and in vitro fertilization
(IVF) outcomes [22, 23, 30].
Of note, two trials were randomized controlled Myo-
Ins versus folic acid, as placebo [20, 25]; three were double-
blind randomized controlled trial Myo-Ins versus folic acid
[11, 21, 26]; one was a randomized controlled Myo-Ins versus
metformin [27]. One study was a dose-response study of D-
chiro-Ins on ovaries [28]. A single study, RCT, also compared
the efficacy between Myo-Ins and D-chiro-Ins in improving
oocyte quality [29]. In the last 3 RCTs, the combination of
Myo-Ins/D-chiro-Ins (40 : 1) was examined in PCOS patients
[22, 23, 30].
In the report of Genazzani et al. [20], PCOS patients
were recruited in the trial and treated with either Myo-Ins
plus folic acid (Inofolic, LO.LI. Pharma, Rome, Italy) or
folic acid alone (Table 1).The endocrine profile was evaluated
and main outcomes are shown in Table 3. Consistent and
significant changes were observed in the group receiving
Myo-Ins plus folic acid. Indeed, prolactin (PRL), plasma
luteinizing hormone (LH), and follicle stimulating hormone
(FSH) ratio significantly decreased. The index of insulin
sensitivity, expressed as glucose-to-insulin ratio, significantly
increaed. The Ferriman-Gallwey score decreased after 12
weeks of Myo-Ins administration although the reduction was
not statistically significant (22.7 ± 1.4 to 18.0 ± 0.8) whereas
the reduction of the ovaries volumes was significant (12.2 ±
0.6mL to 8.7 ± 0.8mL, 𝑝 < 0.05).
The study design and the endocrine profile after treatment
obtained in the RCT of Costantino et al. [21] are shown in
Tables 1 and 3. During the present study, a reduction in the
systolic and diastolic blood pressure (SBP and DBP) values
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was observed in patients treatedwithMyo-Ins (131±2mmHg
to 127 ± 2mmHg and 88 ± 1mmHg to 82 ± 3mmHg,
resp.), while these values increased in placebo group (128 ±
1mmHg to 130 ± 1mmHg, 𝑝 = 0.002, and 86 ± 7mmHg
to 90 ± 1mmHg, 𝑝 = 0.001, resp.). Furthermore, in
Myo-Ins group, plasma triglycerides decreased from 195 ±
20mg/dL to 95 ± 17mg/dL and total cholesterol significantly
decreased from 210±10mg/dL to 171±11mg/dL. InMyo-Ins-
treated group the composite whole body insulin sensitivity
index (ISI) increased significantly from 2.80 ± 0.35mg/dL
to 5.05 ± 0.59mg/dL, while it did not change in placebo
group. Ovulationwas restored in 69.5% of women inMyo-Ins
group and 21% of placebo (𝑝 = 0.001). After treatment, the
peak level of progesterone (P) was higher inMyo-Ins patients
(15.1 ± 2.2 ng/mL) compared to placebo. Furthermore, there
was a significant reduction of more than 50% in the serum
dehydroepiandrosterone sulphate in Myo-Ins women (366 ±
47 𝜇g/dL to 188 ± 24 𝜇g/dL; 𝑝 = 0.003), whereas it was not
significant in placebo.
Gerli et al. [10, 11] evaluated the effect of Myo-Ins on
ovarian andmetabolic factors in PCOS subjects, in 2 different
studies conducted in 2003 and 2007 (Tables 1 and 3); in
the first trial [10], the ovulation frequency was significantly
higher (𝑝 < 0.01) in Myo-Ins-treated group (23%) compared
with placebo (13%). The main outcomes are defined in
Table 3. In addition, it was found that E2 concentration
increased only in Myo-Ins group during the first week of
treatment inducing follicular maturation. The body mass
index (BMI) and leptin were significantly reduced in treated
patients, whereas body weight augmented in placebo. A
significant increase in circulating high-density lipoprotein
(HDL) was recorded inMyo-Ins women. In the second study
[11], in addition to the main findings shown in Table 3, a
significant increment of the ovulation frequency in Myo-Ins
group compared to placebo was observed. All patients started
treatment outside the luteal phase, and the delay to the first
ovulation after starting the program was significantly shorter
in the study group (24.5 versus 40.5, 𝑝 = 0.02). The analysis
on the first and eighth day of treatment showed that the
Myo-Ins-treated group had a significant increase in E2 levels
(𝑝 = 0.03), whereas controls showed no change. Circulating
levels of inhibin B remained unvaried. Circulating leptin
concentration declined in Myo-Ins patients, in contrast to
controls. The low-density lipoprotein (LDL) showed a trend
toward reduction, and the HDL increased significantly in
Myo-Ins group.
In Nordio and Proietti study [22], the combination of
Myo-Ins andD-chiro-Ins versusMyo-Ins alonewas evaluated
(Tables 1 and 3). Either treatmentwas efficacious in improving
the ovulation function andmetabolic parameters. Besides the
main findings displayed in Table 3, a reduction of SBP and
SDBwas observed in both groups (Myo-Ins plus D-chiro-Ins,
131.0 ± 1.6mmHg to 128.0 ± 1.2mmHg and 88.0 ± 3.3 to
80 ± 2mmHg, resp., versus Myo-Ins, 129.0 ± 2.5mmHg to
127 ± 2mmHg and 87.0 ± 2.6mmHg to 82 ± 1mmHg, resp.).
Also BMI and waist-to-hip ratio (WHR) were reduced after
treatment but not significantly.
In a very recent study [23], an improvement of patients’
insulin resistance and ovulatory function was observed after
Myo-Ins and D-chiro-Ins treatment, significantly rebalanc-
ing their endocrine and metabolic profiles (Tables 1 and
3).
Papaleo et al. [25] broaden the clinical use of Myo-Ins
by evaluating its effect on oocyte quality and the ovarian
stimulation protocol for PCOS women (Table 2). As can be
seen in Table 4, the number of oocytes retrieved did not differ
between the two groups, whereas in the group treated with
Myo-Ins the number of immature oocytes and degenerated
oocytes was significantly reduced (1.0 ± 0.9 versus 1.6 ± 1.0;
𝑝 = 0.01), with a trend for increased percentage ofmetaphase
II stage oocytes.
In the study of Ciotta et al. [26], oocyte’s quality was
assessed after the oocyte pick-up during the assisted repro-
ductive technology (ART) procedure in women with PCOS
(Table 2). Besides results shown in Table 4, the number of
immature oocytes resulting significantly reduced in Myo-Ins
group (degenerated oocytes 0.93% versus 14.37%, 𝑝 < 0.02;
germinal vesicles 1.4% versus 9.37%, 𝑝 < 0.02) and the mean
number of transferred embryos was significantly higher.
Raffone et al. [27] compared the effects of metformin
(Glucophage, Merck Pharma) andMyo-Ins (Inofolic, LO.LI.
Pharma, Rome, Italy) on PCOS patients (Tables 2 and 4).
In Myo-Ins group 65% of patients versus 50% of metformin
group restored spontaneous ovulation activity, after a mean
of 14.8 (±1.8) days and 16.7 (±2.5) days from day 1 of the
menstrual cycle, respectively.
Fifty-four women diagnosed with PCOS were selected in
the study of Isabella and Raffone, 2012 [28] (Table 2). Patients
were randomized into 5 groups, including a placebo group
and 4 groups that received 300, 600, 1200, and 2400mg of
D-chiro-Ins (Interquim s.a., Barcelona, Spain) daily, respec-
tively. In addition to themain results reported in Table 4, they
found that high D-chiro-Ins concentrations progressively
increase the number of immature oocytes, in a significant
manner (𝑝 < 0.04).
As shown in Tables 2 and 4, Unfer et al. [29] compared
the efficacy ofMyo-Ins andD-chiro-Ins in patients diagnosed
with PCOS. The selected ones were randomly divided into
two groups receiving eitherMyo-Ins orD-chiro-Ins (Table 2).
Along with the main findings presented in Table 4, it was
reported that the number of immature oocytes was signif-
icantly lower in Myo-Ins group compared to D-chiro-Ins
group (0.69 ± 0.64 versus 2.23 ± 0.85; 𝑝 < 0.01).
The combination 40 : 1 of Myo-Ins and D-chiro-Ins (Ino-
folic Combi, LO.LI. Pharma, Rome, Italy; patented) was
also evaluated by Colazingari et al. [30], in PCOS patients
undergoing IVF (Table 2). In this study, for evaluation of
results, women age was also taken into account, dividing
them into 2 further categories: ≤35 or >35 years. The com-
bination of Myo-Ins and D-chiro-Ins gave a greater result
in the ovarian stimulation protocol compared to D-chiro-
Ins alone (Table 4). In Myo-Ins plus D-chiro-Ins patients,
oocytes of high quality resulted and the number of degen-
erated oocytes was lower. In particular results showed that
Myo-Ins plus D-chiro-Ins treatment reduced the number of
degenerated oocytes in both age groups (≤35 years old: 1.04±
1.15 versus 1.82 ± 1.55; >35 years old: 1.00 ± 0.91 versus
1.45 ± 0.89).
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4. Discussion
A critical review of the 12 RCTs included in this systematic
review highlights that oral administration of Myo-Ins, alone
or in combination with D-chiro-Ins, is capable of restoring
spontaneous ovulation and improving fertility inwomenwith
PCOS.
Myo-Ins andD-chiro-Ins are 2 of the 9 different stereoiso-
mers of inositol, polyol found in many foods, in particular
cereals, nuts, and fruits as well as in human cells. They exert
important actions in the control of glucose homeostasis and,
when incorporated into phosphoglycans, have been shown
to serve as second messengers involved in the signaling-
transduction cascade of insulin [36, 37]; Myo-Ins and D-
chiro-Ins are also involved in a number of biochemical path-
ways within oocytes [38, 39]. PCOSwomen have lower serum
D-chiro-Ins levels and elevated urinary loss of D-chiro-Ins-
IPG [40]. As noted above, inositol phosphoglycans (IPGs)
are potentially important putative intracellular mediators of
insulin action. It has been demonstrated that, in patients
affected by PCOS, the metabolism of inositol is dysregu-
lated, highlighting the subtle connection between insulin
resistance and inositol deficiency in PCOS patients [41].
Indeed, in women with PCOS, insulin resistance and com-
pensatory hyperinsulinemia due to dysregulation of inositol
metabolismmay actually be themajor underlying cause of the
disorder. Various studies have shown the role of D-chiro-Ins
at low dosage in increasing insulin sensitivity and ovulation
frequency, as well as in decreasing levels of lipid biomark-
ers and serum androgen [12, 13]. D-chiro-Ins is converted
from Myo-Ins through insulin-stimulated NAD-dependent
epimerase. Myo-Ins is the most abundant inositol isomer
within the ovary, as suggested by the fact that approximately
99% of the ovarian intracellular pool of inositol consists of
Myo-Ins [17]. Indeed, it was shown that an increased activity
of epimerase in theca cells of ovaries of PCOS women is
associated with a consistent reduction in the intraovarian
ratio of Myo-Ins to D-chiro-Ins [19]. These experimental
data are in line with the so-called D-chiro-Ins ovarian
paradox posited by Carlomagno et al. [18]; these investigators
advanced the hypothesis that epimerase activity is increased
in the ovaries of PCOS subjects, resulting in a local Myo-
Ins deficiency responsible for the oligoovulation and poor
oocyte quality of the disorder. This hypothesis has drawn
attention to the importance of Myo-Ins and D-chiro-Ins
supplementation in a physiological ratio in order to restore
normal ovary functionality. In fact, a correlation between
Myo-Ins concentration in the follicular fluid and high oocyte
quality was found and a number of studies have reported that
Myo-Ins supplementation is able to improve oocyte quality
[25, 31].
In this systematic review a number of recent articles were
selected in order to critically analyze the roles of Myo-Ins
and D-chiro-Ins, combined or alone, as a treatment of PCOS.
Although there are a number of published articles on the use
of Myo-Ins as a treatment in women with PCOS, only few
of them were designed as RCT. These RCT studies, reviewed
here, support the hypothesis of a primary role of IPGs as
second messengers of insulin signaling and demonstrate that
Myo-Ins supplementation beneficially affects the hormonal
milieu of PCOS patients. Indeed, these trials provide evi-
dence that Myo-Ins reduces insulin levels, probably either by
conversion to D-chiro-Ins (via the epimerase enzyme) or by
serving as substrate for the formation of Myo-Ins-containing
IPGs and D-chiro-Ins-containing IPGs, which would in turn
amplify insulin signaling. In particular, two studies [20, 25]
suggest that deficiency of Myo-Ins and/or D-chiro-Ins might
be an additional cofactor contributing to the pathophysiology
of the insulin resistance of PCOS patients [42]. In these
studies, hormonal parameters improved significantly in all
PCOS patients treated with Myo-Ins [10, 11, 20, 21, 25–27,
29]. In a study by Gerli et al. body weight and circulat-
ing leptin decreased significantly and HDL concentrations
increased significantly in the patients treated with Myo-
Ins, compared with the placebo group, providing the first
indication that Myo-Ins treatment might possibly reduce the
risk of cardiovascular diseases in PCOSwomen.Moreover, in
an equivalency study, Raffone et al. [27] stated that Myo-Ins
improves the pregnancy rate in PCOSwomen.These findings
further support the hypothesis of a key role of IPG as second
messenger of insulin signaling. The oral supplementation of
Myo-Ins might reduce insulin levels, by providing a higher
availability of IPG precursors, in this way improving the
activities of this second messenger of insulin signal [27].
The study by Ciotta et al. demonstrated that Myo-
Ins treatment reduced the number of germinal vesicles
and degenerated oocytes and improved the development of
mature oocytes, as previously reported in experimental data
[43]. The authors concluded that Myo-Ins alone is useful
in PCOS patients as insulin-sensitizer and for induction of
oocyte maturation [26], confirming that Myo-Ins is likely an
important constituent of the follicular microenvironment for
normal nuclear and cytoplasmic oocyte’s development.
As already noted, the role played by D-chiro-Ins in
ovarian physiology is controversial. In this regard, a study in
which different concentrations of D-chiro-Ins were admin-
istrated to nonobese PCOS women with normal insulin
sensitivity undergoing IVF reported that as the dosage of
D-chiro-Ins was progressively increased, oocyte quality and
ovarian response worsened [28]. A possible explanation for
this observation may lie in the different tissue-specific ratios
of Myo-Ins/D-chiro-Ins in different organs (i.e., 100 : 1 in
the ovary) and the diverse physiological roles of inositol
stereoisomers, as Myo-Ins increases glucose cellular uptake
and D-chiro-Ins is involved in glycogen synthesis [33, 44]. In
fact, cells responsible for glycogen storage (such as liver, mus-
cles, and fat cells) contain high levels of D-chiro-Ins, whereas
brain and heart cells contain high concentration of Myo-
Ins, since they require high consumption of glucose. These
data are in line with the D-chiro-Ins paradox hypothesis and
with the data of Unfer et al. (2011) that demonstrated that
Myo-Ins rather than D-chiro-Ins improved oocyte quality
in intracytoplasmic sperm injection cycles [18, 29]. To wit,
Unfer et al. demonstrated that Myo-Ins treatment signifi-
cantly reduced ovarian stimulation days and the IU of r-FSH
administrated and improved both oocyte and embryo quality
in euglycemic PCOS patients when compared with treatment
with D-chiro-Ins. This was also shown in 2009 by Papaleo
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et al. and included in our previous systematic review [14,
25]. However, as demonstrated by Nordio and Proietti, the
combination of Myo-Ins and D-chiro-Ins, at a physiological
ratio of 40 : 1, was able to more quickly restore to normal
the hormonal andmetabolic parameters in overweight PCOS
women than Myo-Ins treatment alone [22]. Bearing in mind
previous studies, the physiological ratio of these two isomers
(40 : 1) seems to be an optimal and promising approach for
the treatment of PCOS disorders [45, 46].
Thismight be due to the synergistic action ofMyo-Ins and
D-chiro-Ins, as they regulate different biological processes.
In fact, the combination of Myo-Ins and D-chiro-Ins may
be particularly beneficial in overweight PCOS women, con-
sidering that Myo-Ins improves the ovulatory function and
D-chiro-Ins rapidly reduces the peripheral hyperinsulinemia.
Notably, Colazingari et al. also reported that combined
therapy of Myo-Ins and D-chiro-Ins, rather than D-chiro-Ins
alone, improved oocyte quality in PCOS women undergoing
ART [30]. This study further corroborates previous data,
suggesting thatD-chiro-Ins supplementation alonemight not
be the optimal or appropriate approach for improving IVF
outcomes in PCOS patients.
Treatment with the combination of Myo-Ins and D-
chiro-Ins has been further investigated by Benelli et al. who
demonstrated that these two molecules, together in a 40 : 1
ratio, improved the endocrine profile and insulin resistance
of obese women with PCOS [23]. An important aspect of
this study was that no relevant side effects were recorded
during combined therapy with Myo-Ins and D-chiro-Ins,
providing further evidence of the safety of the usage of these
two stereoisomers in combination.There is also accumulating
evidence on the beneficial effects of Myo-Ins administration
on reproductive function and the efficacy of combined Myo-
Ins/D-chiro-Ins administration, in the physiological plasma
ratio of 40 : 1, for amelioration of the metabolic aberrations of
PCOS and for restoring spontaneous ovulation [47].
In conclusion, the analysis of these clinical trials high-
lights the salutary effects of Myo-Ins supplementation in
improving several of the hormonal and reproductive distur-
bances of PCOS; furthermore, the analysis lends prominence
to the pivotal role of inositol(s),mainlyMyo-Ins andD-chiro-
Ins, as a safe and effective therapy for PCOS, including an
enhanced oocyte follicular development and oocyte matu-
ration and in stimulation and pregnancy outcomes in IVF
procedures.
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